Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status

Key Takeaways Incyte earned FDA Breakthrough status for INCA033989 to treat essential thrombocythemia patients.Early phase I data showed strong platelet normalization and tolerability across tested doses.Updated results also showed meaningful benefits in CALR-mutant myelofibrosis, alone or with Jakafi.Incyte (INCY) announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989, to treat patients with essential ...